title: Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake.
abstract: Apolipoprotein AIV (apo AIV) and cholecystokinin (CCK) are peptides that act both peripherally and centrally to reduce food intake by decreasing meal size. The present study examined the effects of intraperitoneally administered bolus doses of recombinant apo AIV, CCK-8, and a combination of subthreshold doses of apo AIV and CCK on 4-h food intake in rats that were fasted overnight. Apo AIV at 100 microg/kg reduced food intake significantly relative to the saline control for 1 h, as did doses of CCK-8 at or above 0.125 microg/kg. Doses of apo AIV (50 microg/kg) or CCK (0.06 microg/kg) alone had no effect on food intake. However, when these subthreshold doses of apo AIV and CCK were administered together, the combination produced a significant inhibition of food intake relative to saline controls (P < 0.001), and the duration of the effect was longer than that caused by the administration of either apo AIV or CCK alone. The satiation effect produced by CCK-8 + apo AIV was attenuated by lorglumide, a CCK1 receptor antagonist. We conclude that, whereas the intraperitoneal administration of doses of either recombinant apo AIV or CCK at or above threshold levels reduces food intake, the coadministration of subthreshold doses of the two peptides is highly satiating and works via CCK1 receptor.
authors.affiliation: Dept. of Pathology and Laboratory Medicine, Univ. of Cincinnati, 2120 E. Galbraith Rd., Cincinnati, OH 45237-0507, USA.
authors.forename: Chun Min
authors.initials: CM
authors.lastname: Lo
authors.forename: Dian Ming
authors.initials: DM
authors.lastname: Zhang
authors.forename: Kevin
authors.initials: K
authors.lastname: Pearson
authors.forename: Liyun
authors.initials: L
authors.lastname: Ma
authors.forename: William
authors.initials: W
authors.lastname: Sun
authors.forename: Randall R
authors.initials: RR
authors.lastname: Sakai
authors.forename: W Sean
authors.initials: WS
authors.lastname: Davidson
authors.forename: Min
authors.initials: M
authors.lastname: Liu
authors.forename: Helen E
authors.initials: HE
authors.lastname: Raybould
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Woods
authors.forename: Patrick
authors.initials: P
authors.lastname: Tso
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology*; D001054:Apolipoproteins A / Q000378:metabolism / Q000494:pharmacology*; D001067:Appetite Depressants / Q000378:metabolism / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005247:Feeding Behavior / Q000187:drug effects / Q000502:physiology*; D006727:Hormone Antagonists / Q000494:pharmacology; D007421:Intestine, Small / Q000378:metabolism; D008297:Male; D011377:Proglumide / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012844:Sincalide / Q000378:metabolism / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D000975:Antioxidants; D001054:Apolipoproteins A; D001067:Appetite Depressants; D006727:Hormone Antagonists; C022205:apolipoprotein A-IV; D011377:Proglumide; C048181:lorglumide; D012844:Sincalide